Quarterly Dividends, Clinical Trial Results, Dental Exhibition Updates, and Upcoming Presentation Schedules - Research Report

 Quarterly Dividends, Clinical Trial Results, Dental Exhibition Updates, and
 Upcoming Presentation Schedules - Research Report Quest Diagnostics, Avanir,
                      Sirona, Ligand and Genomic Health

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, December 16, 2013

NEW YORK, December 16, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Quest
Diagnostics Inc. (NYSE: DGX), Avanir Pharmaceuticals (NASDAQ: AVNR), Sirona
Dental Systems Inc. (NASDAQ: SIRO), Ligand Pharmaceuticals Incorporated
(NASDAQ: LGND) and Genomic Health Inc. (NASDAQ: GHDX). Today's readers may
access these reports free of charge - including full price targets, industry
analysis and analyst ratings - via the links below.

Quest Diagnostics Inc. Research Report

On December 6, 2013, Quest Diagnostics Inc. (Quest Diagnostics) announced that
its Board of Directors has declared a quarterly cash dividend in the amount of
$0.30 per share. The Company informed that the dividend will be payable on
January 22, 2014 to shareholders of record of Quest Diagnostics common stock
on January 7, 2014. The Full Research Report on Quest Diagnostics Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=DDD

http://www.analystscorner.com/r/full_research_report/05ba_DGX

Avanir Pharmaceuticals Research Report

On December 10, 2013, Avanir Pharmaceuticals, Inc. (Avanir) announced results
from PRIME, a phase II clinical trial of the investigational drug AVP-923, for
the treatment of central neuropathic pain in patients with multiple sclerosis.
According to the Company, PRIME did not meet the primary efficacy endpoint. In
the study, patients treated with AVP-923 experienced levels of pain reduction
commensurate with those observed in similar studies and the improvement in
pain scores from baseline reached statistical significance; however, there was
no difference between the treatment arms and placebo. Avanir stated that it
plans to review the detailed data from the PRIME study in conjunction with
previously generated data in diabetic peripheral neuropathic pain to determine
next steps for the development of AVP-923 in neuropathic pain. The Full
Research Report on Avanir Pharmaceuticals - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/2ee8_AVNR

Sirona Dental Systems Inc. Research Report

On December 1, 2013, Sirona Dental Systems Inc. (Sirona) issued a press
release providing highlights from the 2013 ADF dental exhibition in Paris,
where the Company once again presented its full range of equipment for dental
practices and labs. According to Sirona, its new intraoral camera APOLLO DI
and the presentation of the continuous digital process chain at the Company
stand interested many attendees. "The key topic at the ADF 2013 was definitely
digital impression taking: It is and will remain the basis for a fast, simple,
efficient workflow between the dental practice and the lab. With the new
APOLLO DI impression-taking system, Sirona offers dentists a highly economical
entry into digital impression taking," explained Lionel Phelipot, General
Manager of Sirona France. "The inexpensive APOLLO DI features easy handling,
precise acquisition and the tried-and-tested Sirona Connect workflow The
impression-taking system consists of an acquisition unit, the APOLLO Connect
software and the APOLLO DI intraoral camera, with which users can record live
digital impressions of a clinical situation." The Full Research Report on
Sirona Dental Systems Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/08e7_SIRO

Ligand Pharmaceuticals Incorporated Research Report

On December 9, 2013, Ligand Pharmaceuticals Inc. (Ligand) announced positive
preclinical data on small-molecule G-CSF receptor agonist at the 55th Annual
Meeting of the American Society of Hematology (ASH) in New Orleans. In
preclinical studies, Ligand evaluated the ability of LGD-7455 to stimulate
neutrophil (white blood cell) counts in cynomolgus monkeys and investigated
the role that metal ions play in the activity of LGD-7455 on the G-CSF
receptor (G-CSFR). Additionally, Ligand examined effects and mechanisms of
LGD-7455 on tumor cell growth. "We are pleased to present this scientifically
important work from one of Ligand's internal un-partnered programs," said
Matthew W. Foehr, Chief Operating Officer of Ligand. "Ligand's R&D team
continues to make scientific advancements like this first reported
proof-of-concept for a small molecule G-CSF in a primate model. Further
optimization of the LGD-7455 series may lead to a novel oral anticancer
therapy that also serves as a supportive care agent to treat neutropenia in
patients receiving bone-marrow suppressive treatments." The Full Research
Report on Ligand Pharmaceuticals Incorporated - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/3b8d_LGND

Genomic Health Inc. Research Report

On December 4, 2013, Genomic Health, Inc. (Genomic Health) announced that the
Company will present results from multiple Oncotype DX® breast cancer test
studies at the 36th Annual CTRC-AACR San Antonio Breast Cancer Symposium,
being held from December 10 to December 14, 2013 at the Henry B. Gonzalez
Convention Center. The Company informed that the presentations include results
from a comparison of risk classification between the Oncotype DX breast cancer
test and other genomic assays. The Full Research Report on Genomic Health Inc.
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/db58_GHDX

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.